Profil
Vasily Andrianov worked as the VP-Clinical Development & Medical Affairs at Inhibrx, Inc. from 2021 to 2024.
He holds a doctorate degree from Pavlov First Saint Petersburg State Medical University.
Ehemalige bekannte Positionen von Vasily Andrianov
| Unternehmen | Position | Ende |
|---|---|---|
| INHIBRX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 30.05.2024 |
Ausbildung von Vasily Andrianov
| Pavlov First Saint Petersburg State Medical University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Inhibrx, Inc.
 Inhibrx, Inc. BiotechnologyHealth Technology Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA. | Health Technology |
